Exploratory Study of Personalized mRNA Vaccine in Patients With Refractory Rhabdomyosarcoma
An Exploratory Study on the Use of mRNA Tumor Vaccines in the Treatment of Refractory Rhabdomyosarcoma
Rhabdomyosarcoma
BIOLOGICAL: mRNA Tumor Vaccine Therapy
Adverse Event, From the first administration of the study drug until the occurrence of death, loss to follow-up, withdrawal of informed consent, initiation of a new anti-tumor therapy, or 21 days after the last dose, whichever comes first.
An Exploratory Study on the Use of mRNA Tumor Vaccines in the Treatment of Refractory Rhabdomyosarcoma